Polymeric micro/nanoparticles: Particle design and potential vaccine delivery applications

Vaccine

Volumn 33, Issue 44, 2015, Pages 5927-5936

  Yue, Hua ^a   Ma, Guanghui ^a,b  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b SynBio Research Platform   (China)

Author keywords

Adjuvant; Antigen loading; Immunological mechanism; Micro nanoparticles; Physiochemical property; Preventive therapeutic vaccine

Indexed keywords

ANTIGEN; NANOPARTICLE; TUMOR VACCINE; UNCLASSIFIED DRUG; VACCINE; WHOLE CELL TUMOR VACCINE; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT; POLYMER;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER GROWTH; CELL DIFFERENTIATION; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; DRUG DELIVERY SYSTEM; ENZYMATIC DEGRADATION; HELPER CELL; HUMAN; HUMORAL IMMUNITY; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNOSTIMULATION; LYSOSOME; METASTASIS INHIBITION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SURFACE CHARGE; SURFACE PROPERTY; T LYMPHOCYTE ACTIVATION; VACCINATION; ANIMAL; ISOLATION AND PURIFICATION; PHARMACEUTICS; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG CARRIERS; HUMANS; NANOPARTICLES; POLYMERS; TECHNOLOGY, PHARMACEUTICAL; VACCINES;

EID: 84947484763     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.100     Document Type: Review

References (70)

1. Plotkin S. History of vaccination. Proc Natl Acad Sci U S A 2014, 111(34):12283-12287.
2. Blower S.M., Koelle K., Kirschner D.E., Mills J. Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety. Proc Natl Acad Sci U S A 2001, 98(6):3618-3623.
3. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants putting innate immunity to work. Immunity 2010, 33(4):492-503.
4. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012, 104(8):599-613.
5. Silva J.M., Videira M., Gaspar R., Preat V., Florindo H.F. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release 2013, 168(2):179-199.
6. Cheever M.A., Higano C.S.P.R.O.V.E.N.G.E. (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011, 17(11):3520-3526.
7. Banday A.H., Jeelani S., Hruby V.J. Cancer vaccine adjuvants - recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol 2015, 37(1):1-11.
8. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9(4):287-293.
9. Xiang S.D., Scalzo-Inguanti K., Minigo G., Park A., Hardy C.L., Plebanski M. Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines 2008, 7(7):1103-1119.
10. Cheng Z., Al Zaki A., Hui J.Z., Muzykantov V.R., Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338(6109):903-910.
11. van Riet E., Ainai A., Suzuki T., Kersten G., Hasegawa H. Combatting infectious diseases; nanotechnology as a platform for rational vaccine design. Adv Drug Deliv Rev 2014, 74C:28-34.
12. Singh M., Chakrapani A., O'Hagon D. Nanoparticles and microparticles as vaccine-delivery systems. Exp Rev Vaccines 2007, 6(5):797-808.
13. Zhao L., Seth A., Wibowo N., Zhao C.X., Mitter N., Yu C., et al. Nanoparticle vaccines. Vaccine 2014, 32(3):327-337.
14. Zhou W., Moguche A.O., Chiu D., Murali-Krishna K., Baneyx F. Just-in-time vaccines: biomineralized calcium phosphate core-immunogen shell nanoparticles induce long-lasting CD8(+) T cell responses in mice. Nanomedicine 2014, 10(3):571-578.
15. Carcaboso A.M., Hernandez R.M., Igartua M., Rosas J.E., Patarroyo M.E., Pedraz J.L. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 2004, 22(11-12):1423-1432.
16. Shah R.R., O'Hagan D.T., Amiji M.M., Brito L.A. The impact of size on particulate vaccine adjuvants. Nanomedicine (Lond) 2014, 9(17):2671-2681.
17. Rice-Ficht A.C., Arenas-Gamboa A.M., Kahl-McDonagh M.M., Ficht T.A. Polymeric particles in vaccine delivery. Curr Opin Microbiol 2010, 13(1):106-112.
18. Ferreira S.A., Gama F.M. Biodegradable polymeric nanoparticles as vaccine delivery systems. Vaccine 2008.
19. Akagi T., Baba M., Akashi M. Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine. Polym Nanomed 2012, 247:31-64.
20. Oyewumi M.O., Kumar A., Cui Z.R. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Exp Rev Vaccines 2010, 9(9):1095-1107.
21. Wang L.Y., Ma G.H., Su Z.G. Preparation of uniform sized chitosan microspheres by membrane emulsification technique and application as a carrier of protein drug. J Control Release 2005, 106(1-2):62-75.
22. Liu R., Ma G.H., Meng F.T., Su Z.G. Preparation of uniform-sized PLA microcapsules by combining Shirasu Porous Glass membrane emulsification technique and multiple emulsion-solvent evaporation method. J Control Release 2005, 103(1):31-43.
23. Wei Q., Wei W., Tian R., Wang L.Y., Su Z.G., Ma G.H. Preparation of uniform-sized PELA microspheres with high encapsulation efficiency of antigen by premix membrane emulsification. J Colloid Interface Sci 2008, 323(2):267-273.
24. Wei W., Yuan L., Hu G., Wang L.Y., Wu H., Hu X., et al. Monodisperse chitosan microspheres with interesting structures for protein drug delivery. Adv Mater 2008, 20(12):2292-2296.
25. Ma G.H. Microencapsulation of protein drugs for drug delivery: strategy, preparation, and applications. J Control Release 2014, 193:324-340.
26. Flinsenberg T.W., Compeer E.B., Boelens J.J., Boes M. Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention. Clin Exp Immunol 2011, 165(1):8-18.
27. Mitragotri S., Lahann J. Physical approaches to biomaterial design. Nat Mater 2009, 8(1):15-23.
28. Gupta V., Ahsan F. Influence of PEI as a core modifying agent on PLGA microspheres of PGE(1), a pulmonary selective vasodilator. Int J Pharm 2011, 413(1-2):51-62.
29. Kanchan V., Panda A.K. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 2007, 28(35):5344-5357.
30. Cohen J.A., Beaudette T.T., Tseng W.W., Bachelder E.M., Mende I., Engleman E.G., et al. T-cell activation by antigen-loaded pH-sensitive hydrogel particles in vivo: the effect of particle size. Bioconjug Chem 2009, 20(1):111-119.
31. Yue H., Wei W., Yue Z.G., Lv P.P., Wang L.Y., Ma G.H., et al. Particle size affects the cellular response in macrophages. Eur J Pharma Sci 2010, 41(5):650-657.
32. Yue H., Wei W., Fan B., Yue Z.G., Wang L.Y., Ma G.H., et al. The orchestration of cellular and humoral responses is facilitated by divergent intracellular antigen trafficking in nanoparticle-based therapeutic vaccine. Pharmacol Res 2012, 65(2):189-197.
33. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25(10):1159-1164.
34. Pan Y., Leifert A., Ruau D., Neuss S., Bornemann J., Schmid G., et al. Gold nanoparticles of diameter 1.4nm trigger necrosis by oxidative stress and mitochondrial damage. Small 2009, 5(18):2067-2076.
35. Lundqvist M., Stigler J., Elia G., Lynch I., Cedervall T., Dawson K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A 2008, 105(38):14265-14270.
36. Ma Y.F., Zhuang Y., Xie X.F., Wang C., Wang F., Zhou D.M., et al. The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses. Nanoscale 2011, 3(5):2307-2314.
37. Yotsumoto S., Aramaki Y., Kakiuchi T., Tsuchiya S. Induction of antigen-dependent interleukin-12 production by negatively charged liposomes encapsulating antigens. Vaccine 2004, 22(25-26):3503-3509.
38. Yue Z.G., Wei W., Lv P.P., Yue H., Wang L.Y., Su Z.G., et al. Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles. Biomacromolecules 2011, (7):2440-2446.
39. Chen X., Liu Y., Wang L., Liu Y., Zhang W., Fan B., et al. Enhanced humoral and cell-mediated immune responses generated by cationic polymer-coated PLA microspheres with adsorbed HBsAg. Mol Pharma 2014, 11(6):1772-1784.
40. Nel A.E., Madler L., Velegol D., Xia T., Hoek E.M.V., Somasundaran P., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8(7):543-557.
41. Yue Z.G., You Z.X., Yang Q.Z., Lv P.P., Yue H., Wang B., et al. Molecular structure matters: PEG-b-PLA nanoparticles with hydrophilicity and deformability demonstrate their advantages for high-performance delivery of anti-cancer drugs. J Mater Chem B 2013, 1(26):3239-3247.
42. Liu Y., Yin Y., Wang L.Y., Zhang W.F., Chen X.M., Yang X.X., et al. Surface hydrophobicity of microparticles modulates adjuvanticity. J Mater Chem B 2013, 1(32):3888-3896.
43. Liu Y., Yin Y., Wang L.Y., Zhang W.F., Chen X.M., Yang X.X., et al. Engineering biomaterial-associated complement activation to improve vaccine efficacy. Biomacromolecules 2013, 14(9):3321-3328.
44. Powell T.J., Palath N., DeRome M.E., Tang J., Jacobs A., Boyd J.G. Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo. Vaccine 2011, 29(3):558-569.
45. John A.L.S., Chan C.Y., Staats H.F., Leong K.W., Abraham S.N. Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nat Mater 2012, 11(3):250-257.
46. Mathaes R., Winter G., Besheer A., Engert J. Non-spherical micro- and nanoparticles: fabrication, characterization and drug delivery applications. Expert Opin Drug Deliv 2015, 12(3):481-492.
47. Champion J.A., Katare Y.K., Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release 2007, 121(1-2):3-9.
48. Geng Y., Dalhaimer P., Cai S., Tsai R., Tewari M., Minko T., et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2007, 2(4):249-255.
49. Yue Z.G., Wei W., You Z.X., Yang Q.Z., Yue H., Su Z.G., et al. Iron oxide nanotubes for magnetically guided delivery and pH-activated release of insoluble anticancer drugs. Adv Funct Mater 2011, 21(18):3446-3453.
50. Barua S., Yoo J.W., Kolhar P., Wakankar A., Gokarn Y.R., Mitragotri S. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci U S A 2013, 110(9):3270-3275.
51. Agarwal R., Singh V., Jurney P., Shi L., Sreenivasan S.V., Roy K. Mammalian cells preferentially internalize hydrogel nanodiscs over nanorods and use shape-specific uptake mechanisms. Proc Natl Acad Sci U S A 2013, 110(43):17247-17252.
52. Galloway A.L., Murphy A., DeSimone J.M., Di J., Herrmann J.P., Hunter M.E., et al. Development of a nanoparticle-based influenza vaccine using the PRINT (R) technology. Nanomed Nanotechnol Biol Med 2013, 9(4):523-531.
53. Yue H., Wei W., Yue Z., Wang B., Luo N., Gao Y., et al. The role of the lateral dimension of graphene oxide in the regulation of cellular responses. Biomaterials 2012, 33(16):4013-4021.
54. Varshochian R., Jeddi-Tehrani M., Mahmoudi A.R., Khoshayand M.R., Atyabi F., Sabzevari A., et al. The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur J Pharma Sci 2013, 50(3-4):341-352.
55. Yadav S.C., Kumari A., Yadav R. Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation. Peptides 2011, 32(1):173-187.
56. Singh M., Li X.M., Wang H.Y., McGee J.P., Zamb T., Koff W., et al. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect Immun 1997, 65(5):1716-1721.
57. Zhang W., Wang L., Liu Y., Chen X., Liu Q., Jia J., et al. Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation. Biomaterials 2014, 35(23):6086-6097.
58. Zhang W.F., Wang L.Y., Liu Y., Chen X.M., Li J.H., Yang T.Y., et al. Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis. Pharmaceut Res 2014, 31(4):1015-1031.
59. Ju Y., Fan H., Liu J., Hu J., Li X., Li C., et al. Heat shock protein gp96 adjuvant induces T cell responses and cross-protection to a split influenza vaccine. Vaccine 2014, 32(23):2703-2711.
60. Wilson J.T., Keller S., Manganiello M.J., Cheng C., Lee C.C., Opara C., et al. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano 2013, 7(5):3912-3925.
61. Palucka K., Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013, 39(1):38-48.
62. Shirota H., Klinman D.M. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Exp Rev Vaccines 2014, 13(2):299-312.
63. Richard I., Thibault M., De Crescenzo G., Buschmann M.D., Lavertu M. Ionization behavior of chitosan and chitosan-DNA polyplexes indicate that chitosan has a similar capability to induce a proton-sponge effect as PEI. Biomacromolecules 2013, 14(6):1732-1740.
64. De Koker S., De Geest B.G., Singh S.K., De Rycke R., Naessens T., Van Kooyk Y., et al. Polyelectrolyte microcapsules as antigen delivery vehicles to dendritic cells: uptake, processing, and cross-presentation of encapsulated antigens. Angew Chem Int Ed 2009, 48(45):8485-8489.
65. Wu J., Wei W., Wang L.Y., Su Z.G., Ma G.H. Preparation of uniform-sized pH-sensitive quaternized chitosan microsphere by combining membrane emulsification technique and thermal-gelation method. Colloids Surf B 2008, 63(2):164-175.
66. Wang Y.Q., Wu J., Fan Q.Z., Zhou M., Yue Z.G., Ma G.H., et al. Novel vaccine delivery system induces robust humoral and cellular immune responses based on multiple mechanisms. Adv Healthc Mater 2014, 3(5):670-681.
67. Thomas S.N., van der Vlies A.J., O'Neil C.P., Reddy S.T., Yu S.S., Giorgio T.D., et al. Engineering complement activation on polypropylene sulfide vaccine nanoparticles. Biomaterials 2011, 32(8):2194-2203.
68. Flach T.L., Ng G., Hari A., Desrosiers M.D., Zhang P., Ward S.M., et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011, 17(4). 479-U121.
69. Robert L., Atmar M.D., David I., Bernstein M.D., Clayton D., Harro M.D., et al. Norovirus vaccine against experimental human Norwalk Virus illness. New Eng J Med 2011, 365(23):2178-2187.
70. Wu Y.B., Wei W., Zhou M., Wang Y.Q., Wu J., Ma G.H., et al. Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization. Biomaterials 2012, 33(7):2351-2360.